RxDoctor Payments Data

Ana Cerrato-Young

Psychiatric/Mental Health · Chadron, NENPI 1720327752

Payments from drug & device makers

$1,978in general payments, 2019–2025

Across 97 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$498
  • Teva Pharmaceuticals USA, Inc.$491
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$309
  • AbbVie$172
  • Supernus Pharmaceuticals, Inc.$116
  • E.r. Squibb & Sons, L.L.C.$94
  • plus $298 from 6 others

What the payments were for

  • Food & beverage$1,76589%
  • Education$21311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,978 in reported general payments places this provider in the 65th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$33,033
Medicare patients
69
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$168,579
Invega SustennaPaliperidone Palmitate27$86,787
RexultiBrexpiprazole21$32,232
CaplytaLumateperone Tosylate18$30,480
Paliperidone ErPaliperidone64$20,624
Lurasidone Hcl19$11,040
Clozapine OdtClozapine11$6,463
Quetiapine Fumarate201$2,417
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$2,142
Prazosin Hcl99$1,516
Aripiprazole38$1,325
Atomoxetine Hcl15$1,296
Oxcarbazepine51$1,236
Quetiapine Fumarate ErQuetiapine Fumarate17$1,158
Clozapine21$1,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$58$168,57921 claims
Johnson & JohnsonInvega Sustenna$65$86,78727 claims
Otsuka America Pharmaceutical, Inc.Rexulti$498$32,23221 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$309$30,48018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Chadron

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →